Biocon And Zentiva Sign Liraglutide Deal For 30 European Countries
Zentiva Strengthens Positions As Generics Player In Europe
Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.
You may also be interested in...
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Zentiva has made some high-profile changes to its senior leadership team in recent weeks. Former general manager of its Czech Republic and Slovakia business Soňa Porubská is taking on a new role as global head of corporate affairs, succeeded by Boris Sananes.